Article: Combined Metabolic Activators Reduce Liver Fat by Boosting Mitochondria: Preclinical Findings

PrevNext
Liver Disease Liver Health Preclinical

Combined Metabolic Activators Reduce Liver Fat by Boosting Mitochondria: Preclinical Findings

Synopsis

With NAFLD increasing globally and no approved treatments, researchers tested a combination of metabolic activators (including NAD+ precursor nicotinamide riboside, antioxidants, and amino acids) in hamsters fed a fatty liver–inducing diet. Treatment reduced liver fat, improved liver function, and lowered fibrosis and inflammation. Gene analysis showed activation of mitochondrial function and improved lipid, amino acid, and antioxidant metabolism. These results support the benefits of combined metabolic activators in treating fatty liver disease.

Journal

Biomedicines

Share

Read more

Autoimmune Disease

Counteracting CD38-Induced NAD+ Depletion Reduces Multiple Organ Fibrosis: Preclinical Findings

SynopsisSystemic sclerosis (SSc) involves fibrosis in multiple organs, but its cause is not fully understood. NAD+ decline with age and disease, often due to increased CD38 activity (an NADase), ma...

Read more
Healthy Aging & Longevity

Comparison of Metformin and Nicotinamide Riboside in Reducing Tissue Aging: Preclinical Findings

SynopsisMetformin (MET) and nicotinamide riboside (NR) both have potential anti-aging effects, but how they work in different tissues isn't fully clear. This study showed that MET and NR reduce sig...

Read more